An observational study in Interstitial Lung Disease, Venous Thromboembolism and Pulmonary Embolism, sponsored by Sohag University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Sohag University · Observational
This study aims to determine the incidence of venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), among hospitalized patients with interstitial lung disease (ILD). It will also identify potential risk factors associated with VTE and evaluate its impact on clinical outcomes. Patients with ILD admitted to the hospital will be assessed for clinical characteristics, disease severity, risk factors for thrombosis, and the occurrence of DVT or PE during hospitalization. The study findings may help improve early recognition of VTE and guide appropriate preventive and diagnostic strategies in hospitalized patients with ILD.
680 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.
This study's planned enrollment of 100 is below the median of 157 across 278 observational studies indexed under Lung Diseases, Interstitial.
Browse Lung Diseases, Interstitial studies →Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.
Counted across the registry records on this site, refreshed daily.
"The study will include adult patients aged 18 years or older who are admitted to the Department of Chest Diseases, Sohag University Hospital, with a confirmed diagnosis of interstitial lung disease (ILD). Eligible patients will be assessed for risk factors, clinical characteristics, and occurrence of venous thrombotic events during hospitalization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Primary outcome: Incidence of venous thromboembolic events (VTE)
Number and proportion of adult patients with ILD who develop objectively confirmed venous thromboembolic events, defined as DVT and/or pulmonary embolism, during hospitalization.
Time frame: One Year
Length of hospital stay
Time frame: One year
Requirement and level of respiratory support
Time frame: One Year
ICU admission and length of ICU stay
Time frame: One Year
In-hospital mortality
Time frame: One Year
No study locations are listed for this record.
Start is estimated for Sep 2026; primary completion for Aug 2027, 11 months later.
Of 111 non-industry observational studies under Lung Diseases, Interstitial, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 274. This study's planned 11 months is below that.
Counting every sponsor, half of 132 studies reached it within 55 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.